Proposed Dual-Listing on Nasdaq

RNS Number : 6562Y
MaxCyte, Inc.
14 May 2021

Proposed Dual-Listing on Nasdaq


This announcement contains inside information



Gaithersburg, Maryland - May 14, 2021 - MaxCyte, Inc. (LSE: MXCT, MXCL, MXCN) ("MaxCyte" or the "Company"), a leading provider of platform technologies for cell engineering, today announces that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the "Offering").


The number of securities to be offered and the price for the proposed Offering have not yet been determined.  The Offering is expected to commence after the SEC completes its review process, subject to market and other conditions, and shareholders and potential investors should note that the proposed Offering may or may not proceed.


This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the "SecuritiesAct"). This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.


About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. MaxCyte's existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research. MaxCyte has granted 12 strategic platform licences to commercial cell therapy developers. Including these strategic platform licences, MaxCyte has granted research and clinical licences with academic and industry customers covering over an estimated 140 programs, and clinical licences with academic and industry customers covering over an estimated 100 programs being developed for use in humans. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US.




For further information, please contact:


MaxCyte Inc. 

+1 301-944-1660

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer




Nominated Adviser and Joint Corporate Broker

Panmure Gordon

+44 (0)20 7886 2500

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden




Joint Corporate Broker  

Numis Securities Limited 

+44 (0)20 7260 1000

James Black / Duncan Monteith / Matthew O'Dowd




Financial PR Adviser

Consilium Strategic Communications

+44 (0)
203 709 5700

Mary-Jane Elliott / Chris Welsh


US Media Adviser

Jamie Lacey-Moreira


+1 410-299-3310




The person responsible for arranging the release of this announcement on behalf of the Company is Doug Doerfler, President and Chief Executive Officer of MaxCyte, Inc.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100

Latest directors dealings